Investigational drug · Phase 3
Flumatinib
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Chronic Myeloid Leukemia.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 21, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
15
Any phase or sponsor naming "Flumatinib"
First trial start
2026
Dec 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Flumatinib", any sponsor or status.
Conditions studied
As listed on its trial records.
- Chronic Myeloid Leukemia
Approved drugs for the same conditions: Chronic myeloid leukemia · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "Flumatinib" as an intervention, largest first.
- A Real World Study of the Efficacy and Safety of Flumatinib Versus Imatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic PhaseNot yet recruiting
Jiangsu Hansoh Pharmaceutical Co., Ltd.Industry
NCT05367765 · 2,400 participants (planned) · Start Apr 30, 2022 · Primary completion Apr 30, 2027
Drug: Flumatinib; Imatinib · For: CML, Chronic Phase
Sites: Harbin, China
- Flumatinib Versus Nilotinib for Newly Diagnosed Chronic Phase Chronic Myeloid LeukemiaStatus unknown
The First Affiliated Hospital of Soochow UniversityAcademic, hospital or other
NCT04739826 · 491 participants (planned) · Start Sep 25, 2020 · Primary completion Jan 2025
Drug: Flumatinib Mesylate; Nilotinib Pill · For: CML, Chronic Phase; TKI
Sites: Suzhou, China
- A Study of HS-10382 Versus Investigator-selected TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CPPivotal-lookingNot yet recruiting
Jiangsu Hansoh Pharmaceutical Co., Ltd.Industry
NCT07885293 · 408 participants (planned) · Start Dec 2026 · Primary completion Jul 2029
Drug: HS-10382; Imatinib and 3 more · For: Chronic Myeloid Leukemia
Sites: Wuhan, China
- The Study of the Efficacy and the Safety of Flumatinib vs Imatinib as First Line Treatment in Patients With CMLPivotal-lookingCompleted
Jiangsu Hansoh Pharmaceutical Co., Ltd.Industry
NCT02204644 · 400 participants · Start Jun 2014 · Primary completion Jun 2017
Drug: Flumatinib 600mg qd; Imatinib 400mg qd · For: CML, CML-CP,MMR,TKI
Sites: Tianjin, China
- De-escalation Strategy of Tyrosine Kinase Inhibitors Before Treatment Discontinuation in Patients With Chronic Myeloid LeukemiaPivotal-lookingNot yet recruiting
Nanfang Hospital, Southern Medical UniversityAcademic, hospital or other
NCT07839988 · 280 participants (planned) · Start Sep 9, 2026 · Primary completion Jul 31, 2030
Drug: Halve TKIs; Withdrawal TKIs · For: Chronic Myeloid Leukemia in Chronic Phase
Sites: Guangzhou, China
Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyAcademic, hospital or other
NCT04681820 · 200 participants (planned) · Start Nov 1, 2020 · Primary completion Dec 2023
Drug: Flumatinib; Nilotinib · For: CML-CP; Mutation;Suboptimal Response or Failure in TKI
Sites: Wuhan, China
Shenzhen Second People's HospitalAcademic, hospital or other
NCT04677439 · 200 participants (planned) · Start Jan 1, 2021 · Primary completion May 30, 2023
Drug: Flumatinib · For: Flumatinib; Chronic Myeloid Leukemia, Chronic Phase; Imatinib
Sites: Shenzhen, China
- A Study of the Efficacy and Safety of Flumatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.Pivotal-lookingStatus unknown
Jiangsu Hansoh Pharmaceutical Co., Ltd.Industry
NCT05353205 · 200 participants (planned) · Start Nov 23, 2021 · Primary completion Dec 30, 2022
Drug: Flumatinib mesylate tablets (400mg); Flumatinib mesylate tablets (600mg) · For: CML, Chronic Phase
Sites: Harbin, China
- A Phase II Study to Evaluate the Efficacy and the Safety of Flumatinib in CML-AP or CML-BP PatientsStatus unknown
Jiangsu Hansoh Pharmaceutical Co., Ltd.Industry
NCT02511340 · 167 participants (planned) · Start Jan 2013 · Primary completion Aug 2015
Drug: Flumatinib mesylate tablet 600 mg qd · For: Chronic Myelogenous Leukemia
Sites: Wuhan, China
- A Phase II Study of Flumatinib Versus Imatinib to Treat Philadelphia Chromosome Positive Chronic Myelogenous LeukemiaPivotal-lookingStatus unknown
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT01503502 · 150 participants · Start Aug 2011 · Primary completion Jun 2012
Drug: flumatinib; imatinib · For: Myelogenous Leukemia, Chronic
Sites: Beijing, China; Wuhan, China; Suzhou, China · 5 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Vision loss as the first manifestation of isolated cns relapse in CML blast crisis during flumatinib maintenance therapy: A case report.
Hong L, Mu J, Yang K, et al. · Medicine (Baltimore) 2026
- First-Line Flumatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: A 3-Month Landmark-Evaluable Real-World Experience.
Chen D, Yao F · Mediterr J Hematol Infect Dis 2026
- Renal dysfunction in patients with CML on long-term first-line TKI therapy: a single-center analysis.
Wang S, Lei Y, Liu S, et al. · Oncologist 2026
- Matching-adjusted indirect comparison between asciminib and flumatinib as first-line treatment for chronic myeloid leukemia in China.
Wang Y, Hui Y, Zhang L, et al. · Transl Cancer Res 2026
- [Efficacy and Long-term Prognosis of Flumatinib in the Treatment of Chronic Myelocytic Leukemia].
Xia L, Bao J, Huang Z, et al. · Sichuan Da Xue Xue Bao Yi Xue Ban 2026
- Optimizing Flumatinib Therapy in Chinese Chronic-Phase Chronic Myeloid Leukemia Based on Therapeutic Drug Monitoring.
Cheng F, Wang F, Cui Z, et al. · Drug Des Devel Ther 2026
Also in development for Chronic Myeloid Leukemia
- OlverembatinibPhase 34 trials
Ascentage Pharma Group Inc. · Ph+ ALL, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive, Relapsed/Refractory Acute Myeloid Leukaemia
- HS-10382MK-4208, Tern-701Phase 32 trials
Jiangsu Hansoh Pharmaceutical Co., Ltd. · Chronic Myeloid Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Chronic Myeloid Leukemia, Chronic Phase
- TGRX-678Phase 32 trials
Shenzhen TargetRx Co., Ltd. · Chronic Myelogenous Leukemia, Chronic Myelogenous Leukemia - Chronic Phase, Chronic Myeloid Leukemia
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.